Drupel Pharmaceutical Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
- Paid Up Capital ₹ 10.00 K
- Company Age 5 Year, 5 Months
- Last Filing with ROC 31 Mar 2024
- Revenue Growth 95.86%
- Profit Growth 27.62%
- Ebitda 16.25%
- Net Worth 48.04%
- Total Assets 7.73%
About Drupel Pharmaceutical
Drupel Pharmaceutical Private Limited (DPPL) is a Private Limited Indian Non-Government Company incorporated in India on 09 September 2019 (Five years and five months 15 days old ). Its registered office is in Kamrup, Assam, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 10.00 K , as per Ministry of Corporate Affairs (MCA) records.
Subir Ghosh, Sujay Ghosh, Sanjoy Ghosh, and One other member serve as directors at the Company.
Company Details
- Location
Kamrup, Assam, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
-
- Social Media -
Corporate Identity Details
- CIN/LLPIN
U33110AS2019PTC019505
- Company No.
019505
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
09 Sep 2019
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Shillong
Industry
Who are the key members and board of directors at Drupel Pharmaceutical?
Board Members (4)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Subir Ghosh  | Director | 09-Sep-2019 | Current |
| Sujay Ghosh | Director | 01-Oct-2020 | Current |
| Sanjoy Ghosh | Director | 01-Oct-2020 | Current |
| Debajit Kar | Director | 09-Sep-2019 | Current |
Financial Performance of Drupel Pharmaceutical.
Drupel Pharmaceutical Private Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 95.86% increase. The company also saw a substantial improvement in profitability, with a 27.62% increase in profit. The company's net worth Soared by an impressive increase of 48.04%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Drupel Pharmaceutical?
Unlock access to Drupel Pharmaceutical's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Drupel Pharmaceutical?
Unlock and access historical data on people associated with Drupel Pharmaceutical, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Drupel Pharmaceutical, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Drupel Pharmaceutical's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.